Skip Nav Destination
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations
Issue Archive
September 27 2012
In this Issue
Table of Contents
Inside Blood
Blood Work
Plenary Paper
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium
CME
Clinical Trials & Observations
David A. Jacobsohn,Brenda F. Kurland,Joseph Pidala,Yoshihiro Inamoto,Xiaoyu Chai,Jeanne M. Palmer,Sally Arai,Mukta Arora,Madan Jagasia,Corey Cutler,Daniel Weisdorf,Paul J. Martin,Steven Z. Pavletic,Georgia Vogelsang,Stephanie J. Lee,Mary E. D. Flowers
Perspectives
Review Article
Clinical Trials and Observations
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
Clinical Trials & Observations
Hervé Ghesquières,Guillaume Cartron,John Francis Seymour,Marie-Hélène Delfau-Larue,Fritz Offner,Pierre Soubeyran,Aurore Perrot,Pauline Brice,Réda Bouabdallah,Anne Sonet,Jehan Dupuis,Olivier Casasnovas,John Vincent Catalano,Alain Delmer,Fabrice Jardin,Aurélie Verney,Peggy Dartigues,Gilles Salles
Hematopoiesis and Stem Cells
Immunobiology
Lymphoid Neoplasia
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Clinical Trials & Observations
María-Victoria Mateos,Albert Oriol,Joaquín Martínez-López,Norma Gutiérrez,Ana-Isabel Teruel,Ana López de la Guía,Javier López,Enrique Bengoechea,Montserrat Pérez,Marta Polo,Luis Palomera,Felipe de Arriba,Yolanda González,Jose-Mariano Hernández,Miquel Granell,José-Luis Bello,Joan Bargay,Francisco-Javier Peñalver,José-María Ribera,María-Luisa Martín-Mateos,Ramón García-Sanz,Juan-José Lahuerta,Joan Bladé,Jesús F. San-Miguel
Multiple myeloma–related deregulation of bone marrow–derived CD34+ hematopoietic stem and progenitor cells
Ingmar Bruns,Ron-Patrick Cadeddu,Ines Brueckmann,Julia Fröbel,Stefanie Geyh,Sebastian Büst,Johannes C. Fischer,Frederik Roels,Christian Matthias Wilk,Frank A. Schildberg,Ali-Nuri Hünerlitürkoglu,Christoph Zilkens,Marcus Jäger,Ulrich Steidl,Fabian Zohren,Roland Fenk,Guido Kobbe,Benedict Brors,Akos Czibere,Thomas Schroeder,Andreas Trumpp,Rainer Haas
Myeloid Neoplasia
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Clinical Trials & Observations
Jorge Cortes,Jeff H. Lipton,Delphine Rea,Raghunadharao Digumarti,Charles Chuah,Nisha Nanda,Annie-Claude Benichou,Adam R. Craig,Mauricette Michallet,Franck E. Nicolini,Hagop Kantarjian,on behalf of the Omacetaxine 202 Study Group
Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT
Raghuveer Singh Mali,Peilin Ma,Li-Fan Zeng,Holly Martin,Baskar Ramdas,Yantao He,Emily Sims,Sarah Nabinger,Joydeep Ghosh,Namit Sharma,Veerendra Munugalavadla,Anindya Chatterjee,Shuo Li,George Sandusky,Andrew W. Craig,Kevin D. Bunting,Gen-Sheng Feng,Rebecca J. Chan,Zhong-Yin Zhang,Reuben Kapur
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
Zhihong Zeng,Yue Xi Shi,Twee Tsao,YiHua Qiu,Steven M. Kornblau,Keith A. Baggerly,Wenbin Liu,Katti Jessen,Yi Liu,Hagop Kantarjian,Christian Rommel,David A. Fruman,Michael Andreeff,Marina Konopleva
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
Brief Report
Anna L. Godfrey,Edwin Chen,Francesca Pagano,Christina A. Ortmann,Yvonne Silber,Beatriz Bellosillo,Paola Guglielmelli,Claire N. Harrison,John T. Reilly,Frank Stegelmann,Fontanet Bijou,Eric Lippert,Mary F. McMullin,Jean-Michel Boiron,Konstanze Döhner,Alessandro M. Vannucchi,Carlos Besses,Peter J. Campbell,Anthony R. Green
Phagocytes, Granulocytes, and Myelopoiesis
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Brief Report
Julien Haroche,Frédéric Charlotte,Laurent Arnaud,Andreas von Deimling,Zofia Hélias-Rodzewicz,Baptiste Hervier,Fleur Cohen-Aubart,David Launay,Annette Lesot,Karima Mokhtari,Danielle Canioni,Louise Galmiche,Christian Rose,Marc Schmalzing,Sandra Croockewit,Marianne Kambouchner,Marie-Christine Copin,Sylvie Fraitag,Felix Sahm,Nicole Brousse,Zahir Amoura,Jean Donadieu,Jean-François Emile
Platelets and Thrombopoiesis
Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression
Dominique Bluteau,Ana C. Glembotsky,Anna Raimbault,Nathalie Balayn,Laure Gilles,Philippe Rameau,Paquita Nurden,Marie Christine Alessi,Najet Debili,William Vainchenker,Paula G. Heller,Remi Favier,Hana Raslova
MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations
Brief Report
Iléana Antony-Debré,Dominique Bluteau,Raphael Itzykson,Véronique Baccini,Aline Renneville,Françoise Boehlen,Margot Morabito,Nathalie Droin,Caroline Deswarte,Yunhua Chang,Guy Leverger,Eric Solary,William Vainchenker,Rémi Favier,Hana Raslova
Thrombosis and Hemostasis
Vascular Biology
Tyrosine phosphorylation of DEP-1/CD148 as a mechanism controlling Src kinase activation, endothelial cell permeability, invasion, and capillary formation
Kathleen Spring,Catherine Chabot,Simon Langlois,Line Lapointe,Nguyen Thu Ngan Trinh,Christine Caron,Jagoda K. Hebda,Julie Gavard,Mounib Elchebly,Isabelle Royal
Correspondence
Errata
Bertilaccio MT, Simonetti G, Dagklis A, et al. Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models. Blood. 2011;118(3):660–669.
Maria Teresa Sabrina Bertilaccio,Giorgia Simonetti,Antonis Dagklis,Martina Rocchi,Tania Veliz Rodriguez,Benedetta Apollonio,Alberto Mantovani,Maurilio Ponzoni,Paolo Ghia,Cecilia Garlanda,Federico Caligaris-Cappio,Marta Muzio
Other Departments
-
Cover Image
Cover Image
![issue cover]()
A subnetwork analysis for patients with CLL disease progression. Nodes and links represent human proteins and protein physical interactions, respectively. Blue links indicate protein-protein interactions; black arrows indicate protein-DNA binding. The color of each node scales with the change in gene expression in patients of shorter versus longer treatment-free survival intervals: red represents up-regulation in patients with shorter intervals whereas green represents down-regulation. The predominant cellular functions are indicated next to each subnetwork. Known cancer susceptibility genes are highlighted by a black asterisk. See the article by Chuang et al on page 2639.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
